Sign up
Pharma Capital

Hemispherx Biopharma updates on current trials, gears up to begin 5 more

Hemispherx Biopharma Inc (NYSE American:HEB) CEO Tom Equels updates Proactive Investors on its US trials with cancer drug candidate Ampligen, and says the biopharma is initiating five additional Ampligen trials this year.

Equels says he'd like to source the $8-10 million needed to begin these new studies from government grants and industry support.

 

View full HEB profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.